NK cells are CD3(−)CD19(−) large granular lymphocytes that can kill infected or malignantly transformed cells and produce cytokines, such as IFN-γ, that regulate the innate and adaptive immune systems. Similar to other lymphocytes, human NK cells are thought to originate from CD34(+) hematopoietic progenitor cells (HPCs) that diff erentiate through discrete stages of maturation (1) . Whereas T and B cell developmental intermediates have been identifi ed within the human thymus and BM, respectively, in vivo stages of human NK cell diff erentiation have not been defi ned.
Our current understanding of NK cell development stems primarily from fi ndings in mice and in vitro diff erentiation systems (1, 2) . Early studies revealed that IL-15 can promote the diff erentiation of cytolytic NK cells from CD34(+) HPCs in vitro (3) . IL-15 signals in part via the IL-2 receptor β chain (CD122), and mice lacking either IL-15 or CD122 have severe NK cell defi ciencies supporting their physiological roles during NK cell development in vivo (4, 5) . Other cytokines, such as fl t3 ligand (FL) and c-kit ligand (KL), can induce the generation of CD122(+) NK cell precursors (NKPs) from IL-15-nonresponsive mouse BM progenitors, indicating that the acquisition of "IL-15 responsiveness" marks a critical stage in mouse NK cell development (6) , and indeed the earliest committed mouse NKPs in vivo express CD122 yet lack other markers of mature NK cells (7) . CD122 expression is also maintained throughout the downstream stages of mouse NK cell diff erentiation, which were recently elucidated by correlating integrin expression patterns with stages of proliferation, receptor expression, and acquisition of NK cell function (8) .
In humans, CD122 expression on freshly isolated CD34(+) HPCs is below the limits of detection by fl ow cytometry, making it difficult to identify IL-15-responsive NKPs (9) (10) (11) . In addition, mouse NK cells express NK1.1 and DX5, whereas human NK cells are generally defi ned by the expression of CD56, which is not expressed by mouse NK cells (1, 2) . Therefore, it has remained a challenge to identify the orthologous NK cell developmental intermediates in humans. However, despite these diff erences in antigen expression between the species, results from in vitro diff erentiation assays initiated with human CD34(+) HPCs have revealed important general consistencies with the in vivo mouse data. Both the human in vitro data as well as the mouse in vivo data indicate that NK cell functional maturity (i.e., the ability to mediate natural cytotoxicity and produce IFN-γ) is acquired at a late stage of development, likely distal to the acquisition of surface CD56 in humans (8, 12, 13) . In addition, similar to mouse NK cell diff erentiation, in vitro human NK cell diff erentiation is associated with the nonrandom, orderly acquisition of NK cell receptors (1, 2) , with CD161 and NKp46 being among the fi rst NK cell receptors to be detected, followed by CD94, and lastly CD16 and killer-cell immunoglobulin-like receptors (KIRs; references 3, 12, 14) . Collectively, these results suggest that human NK cells would diff erentiate through discrete developmental stages in vivo; however, the precise intermediates have not yet been described.
Another major diff erence between mice and humans is that the latter have two NK cell subsets, with the CD56 bright subset being substantially more capable of proliferation and cytokine production, whereas the fresh CD56 dim subset displays a higher capacity for natural cytotoxicity ex vivo (15) . Currently, the developmental relationship between mature human NK cell subsets is unknown as are their sites of differentiation in vivo (1, 15) . Although ≥90% of peripheral blood (PB) NK cells are CD56 dim CD16(+)KIR(+), the majority of NK cells in human LNs and tonsils are CD56 bright CD16(−)KIR(−) (16, 17) . We recently described a population of CD34 dim CD45RA(+) HPCs that is highly enriched with NKPs and that is unique among all CD34(+) subsets by its ability to colocalize within the T cell-rich regions of human LNs near mature CD56 bright NK cells (9) . Based on these fi ndings, we hypothesized that secondary lymphoid tissues (SLT) might be sites of CD56 bright NK cell diff erentiation and would, therefore, contain all the requisite NK cell developmental intermediates spanning the continuum of diff erentiation from a CD34(+) progenitor to a CD56 bright NK cell. In the current study, we identify and functionally characterize such intermediates from SLT, thereby providing a new model for the development of human NK cells in vivo.
RESULTS

Delineation of NK cell developmental stages within human SLT
We noted from previous work that although primary CD56 bright NK cells found in BM and PB coexpress CD94, the majority of CD56 bright NK cells derived in vitro from CD34(+) HPCs cultured in IL-15 lack CD94 (Fig. 1 A; reference 9), suggesting that a CD94(−) intermediate stage may exist in vivo. Interestingly, fresh human SLT contain CD3(−)CD56(+)CD94(−) cells (Fig. 1 A) . We speculated that the latter may be immature NK cell developmental intermediates, and additional phenotypic analyses revealed that these cells are uniformly CD117(+) and some express CD34 (Fig. 1 B) . Based on these results, we made the following three predictions of in vivo human NK cell development. First, given that CD34 and CD94 are mutually exclusive antigens ( Fig. 1 B, right) , a developing NK cell would fi rst lose CD34 before acquiring CD94. Second, as all CD3(−)-CD56(+) cells in SLT express at least either CD117 and/or CD94 ( Fig. 1 B, left) , NK cell developmental intermediates with the CD34(−)CD94(−) phenotype would be identifiable by the expression of CD117. Third, the CD34(+) HPC, which represents the human IL-15-responsive NKP, would express CD117.
Within human SLT, CD117 expression on CD34 dim CD45RA(+) HPCs identifi es a CD56(+) and CD56(−) population (Fig. 1 C) . The gradual up-regulation of CD56 expression seen exclusively on the CD34(+)CD117(+) population suggested that NK cells are derived from this population and that CD34(+)CD117(−) cells may be functionally distinct as it pertains to NK cell developmental potential (Fig.  1 C) . Within the CD34(−) mononuclear fraction of human SLT, CD117 expression is absent on CD3(+) T cells and CD19(+) B cells, whereas CD34(−)CD117(+) cells display a similar gradual up-regulation of CD56 as that seen on CD34(+)CD117(+) HPCs and they uniformly coexpress the pan-NK cell receptor CD161 (Fig. 1 D) . Thus, within both CD34(+) and CD34(−) mononuclear fractions of human SLT, CD117 expression is highly associated with the NK cell lineage.
Given these collective data, we hypothesized that human NK cells diff erentiate through four discrete stages within SLT: 
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including high-density expression within stage 4 being similar to PB CD56 bright NK cells, lends additional support to this paradigm of in vivo human NK cell diff erentiation (Fig. 2) . Through the remainder of the text, we refer to these four populations as stages 1-4.
Surface marker and gene expression profi les of stages 1- 4 To more comprehensively characterize stages 1-4 as they exist in vivo, we fi rst performed fl ow cytometric analyses on freshly isolated stages as found in SLT, with a focus on antigens expressed by either immature HPCs or mature PB NK cells (Fig. 3) . In agreement with our model, antigens previously associated with immature lymphoid progenitors, including HLA-DR, CD10, and integrin β 7 (9, 18) , were detected at stages 1 and 2 yet not at stages 3 and 4. In contrast, similar to the gradual accumulation of CD56 expression within the stages (Fig. 2) , CD2, CD7, and CD11b expression were gradually increased from stage 1 to 4. Notably, the accumulation of CD11b at stages 3 and 4 is consistent with CD11b being a surrogate marker for maturity during in vivo mouse NK cell diff erentiation (8) . However, there were no detectable diff erences in terms of CD43 expression in this regard (Fig. 3) .
Analysis of NK cell receptors on fresh stages 1-4 found within human SLT from multiple donors also revealed a consistent pattern, such that a greater number of these receptors was expressed at each progressive stage of diff erentiation (Fig. 3) . None of the NK cell receptors we analyzed were detected at stage 1. CD161 was consistently the only receptor expressed at stage 2, whereas both CD161 and NKp44 were detected at stage 3. Stage 4 cells expressed CD161, NKp44 (albeit at low levels), NKp46, and NKG2D, and we could also detect the expression of CD16 and CD158b at stage 4 on low percentages of cells, similar to the low level expression of CD16 and KIR on PB CD56 bright NK cells (15) . Similarly, surface expression of CD122 was fi rst noted at stage 3 and only readily detectable at stage 4. In contrast to these data, we could not detect the expression of NKp30 at any of the four stages in SLT (unpublished data).
Next, we compared freshly isolated stages 1-4 for their relative messenger RNA (mRNA) expression of genes important for mouse NK cell development (19) . Fig. 4 (A and  B) shows representative sorts to purify these four populations directly from human SLT. As comparisons for the gene expression assay, we also analyzed each transcript in total PB CD34(+) HPCs and PB CD56 bright NK cells. As a control for methodology, CD34 mRNA was highest among PB CD34(+) HPCs, lower among stages 1 and 2, and invariably undetectable in lysates from stages 3 and 4 and PB CD56 bright NK cells (Fig. 4 C) . Among stages 1-4, CD122 mRNA was fi rst detectable at stage 2, more abundant in stage 3, and relatively more so in stage 4. ETS-1 mRNA is expressed by mature mouse NK cells (20) , and we observed that it was detectable at stages 1 and 2, yet higher at stages 3 and 4. Mice lacking GATA-3 and T-BET display NK cell functional defects (21, 22) , and it has been postulated that GATA-3 may function upstream of T-BET during mouse NK cell diff erentiation (19) . Consistent with this hypothesis, we observed that GATA-3 mRNA expression peaked at stage 3, whereas T-BET mRNA was low or undetectable at stages 1-3, yet relatively much higher at stage 4, comparable to PB CD56 bright NK cells (Fig. 4 C) .
Natural killing and cytokine production of NK cell development stages According to the model of mouse NK cell diff erentiation proposed by Kim et al. (8) , acquisition of the capacities to mediate natural cytotoxicity and produce cytokines occurs at a late stage of maturation in vivo. Limiting cell numbers prevented us from directly assessing such functional capacities of stages 1 and 2 from human SLT. However, we were able to purify enough fresh stage 3 and 4 cells for analyses. As detected by intracellular fl ow cytometry, stages 1-3 lack perforin whereas perforin expression was detected at stage 4 (Fig. 5 A and not depicted). Accordingly, stage 3 cells showed no killing against either K562 or Jurkat target cells, whereas stage 4 cells displayed >30% and >90% specifi c lysis against these targets, respectively (E/T ratio = 20:1; Fig. 5 B) . In the presence of EGTA and MgCl 2 , the combination of which inhibits perforin-mediated killing (13) , an anti-TNF-related apoptosis-inducing ligand (TRAIL) blocking mAb had no eff ect on the ability of stage 4 cells to lyse Jurkat targets, whereas an anti-Fas ligand (FasL) blocking mAb did inhibit killing (Fig. 5 C) . Therefore, under the conditions tested, freshly isolated stage 4 cells mediated both perforin-and FasL-dependent killing but not TRAIL-dependent killing, similar to PB NK cells (13) , whereas stage 3 cells did not mediate natural cytotoxicity via any of the three mechanisms.
Freshly purifi ed stage 3 and 4 cells were also stimulated for 12 h in either the combination of IL-12, IL-15, and IL-18 or PMA, ionomycin, and IL-2 to assess for cytokine (Fig. 5 D) . Similar results were obtained using intracellular fl ow cytometry to detect IFN-γ, and we were also 
unable to detect IFN-γ production by stages 1 and 2 via this method (unpublished data). GM-CSF was detected from both stage 3 and 4 supernatants, although stage 3 cells produced less GM-CSF than stage 4 cells and did so only in the presence of PMA, ionomycin, and IL-2 ( Fig. 5 D) . In contrast, we could not detect the production of either IL-13 or TNF-α after 12-h stimulation of either SLT population (unpublished data). Collectively, these data suggest that functional maturity occurs within stage 4 of NK cell diff erentiation in vivo.
Lineage differentiation potentials of stages 1-4
For functional assessment of the lineage potentials of stages 1-4, we used a series of in vitro diff erentiation assays. Stages 1-4 were fi rst cultured in semi-solid methylcellulose medium containing KL, GM-CSF, IL-3, and erythropoietin. Whereas multiple CFUs of both erythroid and myeloid lineages were derived from a positive control of total PB CD34(+) HPCs, we did not observe any CFUs from stages 1-4 in three separate experiments (unpublished data). Similarly, we observed that in conditions promoting B cell diff erentiation on MS-5 stroma using control cord blood (CB) CD34(+)CD19(−) HPCs, freshly isolated stages 1-4 failed to give rise to any CD10(+)CD19(+) B lineage cells (Fig. 6 A) .
Numerous studies indicate that NK cells are developmentally most closely related to T cells and DCs (18, (23) (24) (25) (26) . We cultured stages 1-4 in FL and IL-7 on the OP9-DL1 cell line, which supports human T cell diff erentiation (27) . After 4-5 wk, stage 1 cells underwent profound expansions, with cell numbers increasing 1.5 × 10 2 -5.4 × 10 3 -fold (Fig. 6 B) . In contrast, stages 2-4 displayed less than one tenth the propensity for proliferation on the OP9-DL1 line. By fl ow cytometry, both stage 1 and 2 cultures contained CD3(+) T cells, which expressed either TCRαβ or TCRγδ receptors, as well as CD3(−)CD4(+/−)CD8(+/−) immature T cells (Fig. 6 B and not depicted) . However, comparison of the absolute numbers of CD3(+) T cells derived from stage 1 (1.37 × 10 5 per 10 3 initiating cells) versus stage 2 (5.7 × 10 3 per 10 3 initiating cells) cells revealed that there was, on average, a 24-fold diff erence (P = 0.024). In contrast to these results, we did not observe the generation of CD3(+) T cells or CD3(−)CD4(+/−)CD8(+/−) immature T cells in human T cell diff erentiation cultures initiated with purifi ed stage 3 or 4 cells (Fig. 6 B and not depicted) . We did observe CD3(−)CD56 bright CD94(+) NK cells (stage 4) in these cultures when initiated with freshly isolated stage 1, 2, and 3 cells (Fig. 6 C) , confi rming that each of these populations is capable of giving rise to stage 4 NK cells.
To assess for DC diff erentiation, purifi ed stages 1-4 were cultured in FL, KL, IL-3, IL-4, GM-CSF, and TNF-α. After 2 wk, cultures initiated with stages 1-3 maintained live cells, although there was an overall net loss in total viable cell number (mean of 0.14-, 0.35-, and 0.28-fold contractions for stage 1-3 populations, respectively). In contrast, stage 4 cells all died in these conditions. Cultured cells were harvested for analysis by fl ow cytometry. By forward scatter (FSC) versus side scatter (SSC) analysis, stage 1 and 2 cultures contained a distinct population that was absent from stage 3 and 4 cultures. Cells grown out from stage 1 and 2 cultures displayed a phenotype consistent with in vitro-derived DCs (HLA-DR(+)CD14(−)CD1a(+/−)) and expressed co-stimulatory molecules (Fig. 7, A and B; references 18, 25) . Further, these cells displayed typical DC morphology (Fig.  7 C) . In contrast, stage 3 cultures contained only smaller cells that did not display the phenotype shown in Fig. 7 B nor the typical DC morphology (unpublished data). Altogether, these results suggest that full commitment to the NK cell lineage may occur at stage 3 of development in vivo.
Ex vivo NK cell developmental progression of stages 1-4
In addition to the phenotypic and functional assays performed on freshly isolated stages 1-4 of NK cell diff erentiation, we cultured these cells ex vivo to evaluate the eff ects of individual cytokines that have been previously shown to support NK cell diff erentiation in vitro (3, 11, 28) and to assess each stage for evidence of lineage progression versus reversibility. Stages 1 and 2 were fi rst purifi ed from human SLT and cultured in IL-15 without any other cytokines or stroma. As predicted from the CD122 mRNA expression data (Fig.  4 C) , after 2 wk nearly all stage 1 cells died with an overall 0.17 ± 0.21-fold decrease in total viable cell number, whereas cultures initiated with stage 2 cells expanded 20.1 ± 9.9-fold (P = 0.0001; Fig. 8 A) . These data suggest that the ability to respond to IL-15 occurs at stage 2 of diff erentiation in vivo. Stage 2 cells cultured in IL-15 primarily became CD3(−)CD34(−)CD56 bright CD161(+) and displayed a pattern of CD117 versus CD94 expression similar to that of total SLT CD3(−)CD56(+) cells in vivo (Fig. 1 B) , indicative of progression to stages 3 and 4 ( Fig. 8 B and  not depicted) .
Next, we cultured stage 1 cells in IL-15 on MS-5 stroma with FL, IL-3, and IL-7 added at the initiation of culture to determine if these additional factors would promote NK cell diff erentiation from stage 1. In bulk culture, we observed profound expansions (37.1 ± 26.9-fold) compared with cultures in IL-15 alone (n = 4, P = 0. (Fig. 8 C) . Thus, stage 1 cells require additional cytokines for diff erentiation into CD56 bright NK cells ex vivo, consistent with the notion that stage 1 cells are less mature than stage 2 cells that can respond to IL-15.
To gain evidence for a progenitor-progeny relationship between stages 1 and 2, respectively, purifi ed cells were cultured in FL, IL-3, IL-7, and IL-15, and then assessed by fl ow cytometry after 4 d. Reproducibly, we observed the appearance of CD34(+)CD117(+) cells in stage 1 cultures, whereas CD34(+)CD117(−) stage 1 cells were not detected in stage 2 cultures (Fig. 8 D) . Furthermore, cultured stage 2 cells displayed lowered CD34 expression than the CD34(+)CD117(+) cells that had been derived from stage 1, suggesting that stage 2 cells were progressing to stage 3 and that the appearance of CD34(+)CD117(+) cells in stage 1 cultures was a result of the de novo generation of these cells rather than contamination by stage 2 cells at day 0. As predicted, after 10 more days of culture in IL-15, we observed the exclusive appearance of CD34(−)CD117(+)CD94(−) stage 3 and CD34(−)CD117(+/−)CD94(+) stage 4 NK cells in cultures initiated with either stage 1 or 2 cells (unpublished data). Thus, under these conditions in vitro, freshly isolated stage 1 cells gave rise to stages 2-4, whereas freshly isolated stage 2 cells gave rise to stages 3 and 4 but not stage 1. 
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Although the results from the OP9-DL1 co-culture experiments demonstrated that freshly isolated stage 3 cells gave rise to stage 4 cells ex vivo, those experiments were performed in the absence of exogenous IL-15 (Fig. 6 C) . Therefore, we cultured freshly isolated stage 3 and stage 4 cells for 2 wk in IL-15 to determine if this cytokine was suffi cient to promote stage 3 to stage 4 diff erentiation ex vivo (Fig. 9) . Both populations proliferated indicating their responsiveness to this cytokine (Fig. 9 A) . However, although neither population up-regulated CD34, we repeatedly observed that only a small fraction (≤2%) of the sorted stage 3 cells were induced to express CD94 (stage 4), whereas fresh stage 4 cells maintained their phenotype, as predicted by our previous results culturing PB CD56 bright NK cells in IL-15 (Fig. 9 B ; reference 9). Therefore, additional factors might be necessary to drive stage 3 to 4 diff erentiation in vivo. We previously observed that co-culture of total SLT CD34(+) HPCs with autologous activated SLT T cells preferentially promoted the diff erentiation of CD56 bright NK cells that express CD94 (unpublished data), suggesting that endogenous factors produced by activated SLT T cells would promote stage 3 to 4 NK cell diff erentiation in vitro. Indeed, in the presence of autologous activated SLT T cells, we observed the de novo generation of CD3(−)CD34(−)CD117(+/−)CD94(+) stage 4 cells in cultures initiated with purifi ed stage 3 cells, whereas CD3(−)CD34(−)CD117(+)CD94(−) stage 3 cells were not observed in cultures initiated with purifi ed stage 4 cells (Fig. 9 B) .
DISCUSSION
The in vivo developmental pathways for human B and T lymphocytes have been generally understood for decades, and this has been important for studying disease processes such as HIV, childhood and adult leukemia, and lymphoma. Although in vivo stages of mouse NK cell diff erentiation were recently described (8), the similar populations in humans have not yet been reported (1, 2) . In this study, we identifi ed four novel populations that appeared to represent discrete stages of a human NK cell developmental continuum within SLT. Each population was isolated directly from these tissues and was shown to be capable of downstream NK cell diff erentiation ex vivo (i.e., stage 1 → stage 2 → stage 3 → stage 4). Further, we demonstrated that each freshly isolated population could be characterized by unique functional and phenotypic attributes and that overall progression through the stages was characterized by the gradual restriction of non-NK cell lineage diff erentiation potential, concomitant with the gradual acquisition of the mature CD56 bright NK cell phenotype, cytokine production, and mediation of natural cytotoxicity. Collectively, these data provide evidence for a new model of in vivo human NK cell diff erentiation.
Many of our results are consistent with previously published mouse and human data on this subject (1, 2, 19, 23, 26) . Specifi cally, we observed that (a) human NK cells share a common developmental origin with T cells and DCs; (b) commitment to the NK cell lineage precedes acquisition of the capacities for IFN-γ production and natural cytotoxicity; (c) the proposed progression of NK cell development in vivo is supported by the observed patterns of CD122, ETS-1, GATA-3, and T-BET mRNA expression; and (d) the expression and accumulation of NK cell receptors is nonrandom during in vivo maturation. In addition, we observed that CD94 expression in vivo correlates with the ability to produce IFN-γ, which is consistent with previous reports of in vitro human NK cell diff erentiation (12) . However, we did observe some functional and phenotypic diff erences between human NK cell intermediates derived in vitro and those purifi ed directly from human SLT. For example, CD3(−)CD56 bright CD94(−) NK cells derived in vitro uniformly express NKp44 and NKp46 (9, 14) , yet these expression patterns were not observed in vivo. Furthermore, whereas CD94(−) immature NK cells derived in vitro can mediate TRAIL-dependent killing and produce large amounts of IL-13 (12, 13), we did not detect these functions from stage 3 intermediates isolated ex vivo. The reasons for these diff erences are not yet known. However, considering that in vivo diff erentiation to a stage 4 cell is associated with the acquisition of the capacities for both natural killing and IFN-γ production, this process is likely to be tightly regulated to ensure self-tolerance and, therefore, may not be fully recapitulated in culture systems currently used to study human NK cell diff erentiation. In addition, we currently do not know the specifi c mechanisms of action of many cytokines, including FL, IL-3, IL-7, and IL-15, that have been previously implicated as critical in this pathway (3, 11, 28) , nor do we yet know whether the cytokines themselves are present in SLT near developing NK cells at the concentrations used to promote NK cell diff erentiation in vitro. Therefore, these discrepancies may result from missing factors and/or the addition of nonphysiological stimuli during NK cell development in vitro.
In light of the aforementioned data, it is also noteworthy that IL-15 stimulation alone was insuffi cient to promote substantial stage 4 diff erentiation from freshly isolated stage 3 cells despite the generation of stage 4 cells in IL-15-supplemented stage 1 and 2 cultures as well as in cultures initiated with BM or PB CD34(+) HPCs (9) . One interpretation of these data is that IL-15 may have induced the diff erentiation of stage 4 cells directly from stage 2, thus bypassing stage 3. However, this is not supported by the fact that CD34 and CD94 are mutually exclusive antigens, both in vitro and in vivo, and we would expect to fi nd some CD34(+)CD94(+) intermediates in human SLT if this was the case. 
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SLT T cells or OP9-DL1 stroma. Therefore, we favor the hypothesis that stage 4 cells are the direct progeny of stage 3 cells in vivo and that this diff erentiation step may require signals other than, or in addition to, IL-15. Moreover, we speculate that signals promoting stage 4 diff erentiation may be common to OP9-DL1 and activated SLT T cell co-cultures as well as to cultures initiated with CD34(+) HPCs.
The work presented here provides new evidence that LNs and tonsils are sites for human NK cell development in vivo. Previous studies established that CD56 bright NK cells predominate in SLT (16, 17) , and we have now demonstrated that these tissues are also naturally and selectively enriched with the full complement of newly discovered intermediates spanning the continuum of NK cell diff erentiation from a CD34 dim CD45RA(+) progenitor to a mature CD56 bright NK cell. However, there are now many new questions that arise from this study. For example, it is still unclear how SLTderived NK cells might be related to NK cells in other compartments in the body. Although SLT stage 4 cells closely resemble PB CD56 bright NK cells in terms of their phenotypic and functional attributes, it is possible that SLT-resident NK cells represent a lineage distinct from that of CD56 bright NK cells in the blood, as has been postulated for human decidual NK cells (29) . In addition, the majority of NK cells in PB are CD56 dim and express high levels of CD16 and KIRs (15) . Based on their phenotypic and functional characteristics, we speculate that PB CD56 dim NK cells might represent the terminally diff erentiated stage of human NK cell development (stage 5). However, we currently lack direct evidence to support this hypothesis and cannot yet formally exclude the possibility that PB CD56 bright and/or CD56 dim NK cells might be derived from distinct NKPs that diff erentiate in the BM.
It is also unclear to what extent stage 4 cells, or any of the other NK cell lineage populations, actually arise within SLT or merely traffi c through these tissues. On the one hand, our fl ow cytometry data provide strong evidence for the existence of ongoing NK cell maturation within these tissues, as for example analysis of CD94 versus CD117 expression reveals a continuous pattern with cells at all points in the spectrum between stages 3 and 4 ( Fig. 1 B) . On the other hand, previous evidence suggests that both PB CD34(+) NKPs and PB CD56 bright NK cells have the capacity to migrate into SLT, given the relatively high expression of l-selectin on these subsets in the blood versus low or undetectable expression within SLT (9, 17, 30) . Therefore, some of these cells, in particular those that we have characterized as stage 4, may have recently migrated into SLT from other sites. In future studies it will be important to determine the relative capacity for NK cell developmental intermediates to recirculate in and out of multiple lymphoid organs, given the potential implications regarding self-tolerance acquisition and overall regulation of this process in vivo.
A primary goal of this study was to identify surface antigens that could be used to specifi cally and positively identify developing human NK cells in vivo, ideally providing an all-inclusive framework on which to base future research on the NK cell developmental pathway. In this regard, CD34, CD117, and CD94 are useful antigens because they are relatively specifi c to the NK cell lineage in SLT, they provide continuity for "following" developing NK cells, and they account for most if not all of the CD3(−)CD56(+) cells within these tissues. However, stages 1-4 as we defi ned them are likely to be functionally heterogeneous, with the potential to identify additional subsets within each of these populations. For example, our fl ow cytometric analyses revealed that stage 1 and 2 cells are heterogeneous with regards to the expression of CD2, CD7, CD10, and CD56. Therefore, in future experiments, it might be determined that the true NK cell progenitors within the stage 1 population are distinct from non-NK lineage cells that share the CD34(+)CD45RA(+)CD117(−) phenotype or that the stage 2 population consists of monocommitted T, DC, and NKP rather than cells with multipotency. Indeed, we cannot rule out these possibilities using the techniques we used in our study. In addition, there are expected to be diff erentiation steps that are downstream of the acquisition of CD94, including those involving the acquisition of CD16 and KIRs. Therefore, future studies are warranted to continue to refi ne the human NK cell developmental pathway in vivo and to elucidate the physiological mechanisms regulating this process in SLT.
MATERIALS AND METHODS
Cell isolation from human tissues. All protocols were approved by the Ohio State University (OSU) Institutional Review Board. The data in this study were generated from the combined analyses of tissue specimens from >50 tonsil and 30 LN donors and we observed no appreciable diff erences between LNs and tonsils by phenotype or functional assays. Normal human tonsils and LNs were obtained within 24 h of elective surgery through the Tissue Procurement Shared Resource of the OSU Comprehensive Cancer Center or from brain dead tissue donors through the National Disease Research Interchange (NDRI). Tissue cells were dispersed through 70-μm cell strainers into sterile PBS followed by fi coll centrifugation. For each donor's tissues, all cells from multiple tonsil pieces or multiple LNs were pooled to obtain suffi cient numbers of NK cell developmental intermediates for the experiments. Mononuclear fractions were depleted of CD3(+) and CD19(+) cells via magnetic negative selection (Miltenyi Biotec). For certain experiments, T and B cell-depleted preparations were either stimulated to detect intracellular IFN-γ production or directly stained with mAbs for phenotypic analyses. Alternatively, CD34(+) cells were enriched from CD3(−)CD19(−) preparations with the CD34 progenitor isolation kit (Miltenyi Biotech), subsequently stained with FITC-conjugated anti-CD45RA, phycoerythrin-conjugated anti-CD117, and APC-conjugated anti-CD34 mAbs (BD Biosciences), and sorted for stage 1 (CD34(+)CD45RA(+)CD117(−)) and stage 2 (CD34(+) CD45RA(+)CD117(+)) populations with a FACSVantage cell sorter (BD Biosciences). Remaining CD3(−)CD19(−)CD34(−) cells were stained with the combination of FITC-conjugated anti-CD94 mAb (clone 131412; R&D Systems), phycoerythrin-conjugated anti-CD117, APC-conjugated anti-CD3, and APC-conjugated anti-CD34 mAbs (BD Biosciences), and stage 3 (CD3-(−)CD34(−)CD117(+)CD94(−)) and stage 4 (CD3(−)CD34(−)CD117-(+/−)CD94(+)) populations were sorted to >99% purity. SLT-derived T cells and BM, PB, and CB (obtained from NDRI) mononuclear cell populations were obtained as previously described (9) .
Flow cytometry. All mAbs used in this paper were purchased from BD Biosciences, except CD16, CD56, CD122, CD158b, NKp30, NKp44, NKp46 (Beckman Coulter), and CD94 (R&D Systems). Flow cytometry and data analyses were performed as previously described (9).
Real-time PCR. RNA extraction and reverse transcription from ≥2 × 10 4 sorted cells were performed as described previously (31) . All primers and probes were designed using Primer Express software (Applied Biosystems) and the sequences are as follows:
Real-time PCR reactions were performed in a sequence detector (ABI prism 7700; Applied Biosystems) as follows: 50°C for 2 min; 95°C for 10 min; and 45 cycles of 95°C for 15 s and 60°C for 1 min. Data were analyzed with the Sequence Detector version 1.6 software to establish the PCR cycle at which fl uorescence exceeded a set threshold, C T , for each sample. Experimental C T values were used to calculate gene-specifi c copy numbers from a standard curve, and the gene-specifi c copy numbers were normalized to ribosomal 18S copy numbers from the same samples.
Cytotoxicity assays and cytokine production. Cytotoxicity assays were performed in 100 μl RPMI-1640 medium with GlutaMAX containing 10% FBS and antibiotics (Invitrogen) in 96-well V-bottom plates (BD Biosciences) with 2 × 10 2 K562 or Jurkat cloned targets stably infected with mouse stem cell virus retrovirus to express the fi refl y luciferase enzyme. After 8-h incubations, cell pellets were lysed with passive lysis buff er (Promega) and frozen at −80°C. 25 μl of thawed lysates were transferred into Costar 96-well fl at-bottom solid-white plates (Fisher Scientifi c) and mixed with 100 μl of Luciferase assay reagent (Promega) by a Fluoroskan Ascent FL luminometer (Thermo Electron, Inc.). Luminescence was measured as relative light units (RLU) during 10-s intervals. The percent of specifi c lysis for each experiment was calculated as [(mean RLU from wells containing target cells only) − (mean RLU from experimental wells)]/(mean RLU from wells containing target cells only) × 100%. Blocking experiments with the Jurkat cell line were performed with 1 mM EGTA and 2 mM MgCl 2 . The anti-TRAIL (clone RIK-2), anti-FasL (clone NOK-2), and isotype-matched control mAbs (BD Biosciences) were used at 10 μg/ml.
For cytokine production, 2 × 10 4 purifi ed stage 3 or 4 cells were stimulated in either the combination of 10 ng/ml IL-12 (Genetics Institute), 100 ng/ml IL-15, and 100 ng/ml IL-18 (BASF) or 50 ng/ml PMA (SigmaAldrich), 1 μM ionomycin (Calbiochem), and 1 nM IL-2 (Hoff man LaRoche) for 12 h at 37°C. Supernatants were analyzed by ELISA for the production of IFN-γ as described previously (32) using commercially available mAbs (Endogen) or for the production of GM-CSF, TNF-α, and IL-13 using Quantikine ELISA kits (R&D Systems).
Cell culture. Stroma-free cultures were in 96-well round-bottom plates (BD Biosciences) in 200 μl RPMI-1640 medium with GlutaMAX (Invitrogen), 10% heat-inactivated human AB serum (ICN Biomedicals), antibiotics and additional supplements previously described (9) . Recombinant human IL-15 was provided by Amgen and used at 1 nM. Human KL (Amgen) and FL (Peprotech) were used at 100 ng/ml, whereas human IL-3, IL-4, IL-7, G-CSF, GM-CSF, and TNF-α (R&D Systems) were used at 10 ng/ml each. performed with MethoCult GF + from StemCell Technologies following the manufacturer's protocol. T cell diff erentiation cultures on the OP9-DL1 cell line (provided by J.C. Zúñiga-Pfl ücker, University of Toronto, Toronto, Canada) were maintained in α-MEM plus 20% FBS, antibiotics, FL, and IL-7 and were performed as described previously (27) . Morphologies of in vitroderived DCs were assessed via cytospin and Wright/Giemsa staining.
Limiting dilution analysis. Purifi ed stage 1 and 2 cells were cultured at 50, 25, 12.5, 6.25, 3.125, and 1.5625 cells per well, 10 replicates each, on MS-5 stroma in either IL-15 alone or IL-15 with the one time addition of FL, IL-3, and IL-7 at the initiation of culture. Half the medium was changed every 3-4 d to replenish IL-15 only. It was confi rmed that all live human cells remaining in such cultures after 3 wk were CD56 bright NK cells (unpublished data). Therefore, wells that contained visible growth (compared with wells not seeded with HPCs) were scored positive for NK cells, whereas wells that did not contain visible growth were harvested, stained with phycoerythrin-conjugated anti-CD56 mAb, and assessed by fl ow cytometry for the presence or absence of CD56 bright NK cells. NKP frequencies reported in the text were calculated as the reciprocal of the concentration of cells that resulted in ≥63% positive wells using Poisson statistics and the weighted mean method, as described previously (11) .
Statistical analyses. Data were log transformed and analyzed using a paired Student's t test to obtain p-values. S-Plus version 6.0 and SAS version 8.02 software were used for the analyses.
